Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1- seropositive individuals

AIDS Research and Human Retroviruses

Volumn 16, Issue 4, 2000, Pages 337-343

  Seth, Aruna ^a   Yasutomi, Yasuhiro ^a   Jacoby, Helen ^a   Callery, Joan C ^a   Kaminsky, Stephen M ^b   Koff, Wayne C ^c,d   Nixon, Douglas F ^e   Letvin, Norman L ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c United Biomedical Inc   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; LIPOPEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; FEMALE; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SEROLOGY; VIRUS LOAD;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HUMANS; LIPOPROTEINS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; PILOT PROJECTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL LOAD;

EID: 0034052914     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309214     Document Type: Article

References (25)

1. 1. Rinaldo CR, Beltz LA, Huang XL, Gupta P, Fan Z, and Torpey DJ: Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses 1995;11:481-489.
2. 2. Musey L, Hughes J, Schacker T, Shea T, Corey L, and McElrath MJ: Cytotoxic T cell responses, viral load and disease progression in early human immunodeficiency virus type I infection. N Engl J Med 1997;337:1267-1274.
3. 3. Altman JD, Moss PAH, Goulder PJR, et al.: Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
4. 4. Ferrari G, Humphrey W, McElrath MJ, et al.: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94: 1396-1401.
5. 5. Silicano RF, Pollinger RC, Callahan KC, et al.: Clonal analysis of T cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients. AIDS Res Hum Retroviruses 1992;8:1349-1352.
6. 6. Hu SL, Fultz PN, McClure HM, et al.: Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (London) 1987;328:721-723.
7. 7. Shen L, Chen ZW, Miller MD, et al.: Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991;252:440-443.
8. 8. Hu SL, Abrams K, Barber GN, et al.: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
9. 9. Letvin NL, Montefiori DC, Yasutomi Y, et al.: Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997; 94:9378-9383.
10. 10. Boyer JD, Ugen KE, Wang B, et al.: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med 1997;3:526-532.
11. 11. Yasutomi Y, Palker TJ, Gardener MU, et al.: Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993;151:5096-5105.
12. 12. Deres K, Schild H, Wiesmuller KH, Jung G, and Rammensee HG: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (London) 1989;342:561-564.
13. 13. Ahlers JD, Takeshita T, Pendleton CD, and Berzofsky JA: Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 1997;94:10856-10861.
14. 14. Hioe CE, Qiu H, Chend PD, et al.: Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 1996;14:412-418.
15. 15. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, and McMichael AJ: HIV-1 Gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (London) 1984;336:484-487.
16. 16. Nixon DF and McMichael AJ: Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991;5:1049-1059.
17. 17. Buseyne F, McChesney M, Porrot F, Kovarik S, Guy B, and Riviere Y: Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol 1993; 67:694-702.
18. 18. Johnson RP, Trocha A, Yang L, et al: HIV-1 Gag-specific cytotoxic T lymphocytes recognise multiple highly conserved epitopes: Fine specificity of the Gag-specific response by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991;147:1512-1521.
19. 19. Wahren B, Rosen J, Sandstrom E, Mathiesen T, Modrow S, and Wigzell H: HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acquir Immune Defic Syndr 1989;2:448-456.
20. 20. Bourgault I, Chirat F, Tartar A, et al.: Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG-or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol 1994;152:2530-2537.
21. 21. Vitiello A, Ishioka G, Grey M, et al.: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-349.
22. 22. Gotch FM, Nixon DF, Alp N, McMichael AJ, and Borysiewicz LK: High frequency of memory and effector Gag-specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol 1990;2:707.
23. 23. Fast PE and Walker MC: Human trials of experimental AIDS vaccines. AIDS Suppl 1992/1993:S147-S159.
24. 24. Luo L, Li Y, Cho S-Y, et al: Induction of V3-specific cytotoxic T lymphocyte responses by HIV Gag particles carrying multiple immunodominant V3 epitopes of gp120. Virology 1998;240:316-325.
25. 25. Letvin NL: Progress in the development of an HIV-1 vaccine. Science 1998;280:1875-1880.